Delivery Order SPE2DR25D1202-SPE2DR26F71UG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of XCOPRI 50 MG tablets (30-count packages) valued at $7,622.85. This firm fixed-price delivery order represents a non-competitive award and carries an ultimate completion date of August 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,768.44 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a $1,877.45 delivery order to AmerisourceBergen Drug Corp for XCOPRI 200 mg tablets (30-count units) on June 16, 2025, with a completion date of June 17, 2025. This firm fixed-price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,964.26 to AmerisourceBergen Drug Corp for 30 tablets of XCOPRI 100 mg on August 20, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price, competitively awarded contract is not associated with a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, served as the prime contractor for this pharmaceutical delivery. The order represents a relatively...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for the supply of XCOPRI 25 mg tablets (30-count unit) with a contract ceiling value of $4,598.67. This firm fixed-price delivery order, with an ultimate completion date of July 11, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $3,536.88 delivery order to AmerisourceBergen Drug Corp for XCOPRI 25 mg tablets (30-count units) with a firm fixed price structure. The contract, which was competitively awarded without set-aside designation, is scheduled for completion by June 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $3,811.64 delivery order to AmerisourceBergen Drug Corp for XCOPRI 100 mg tablets (30-unit supply) on September 17, 2025, with completion scheduled for September 18, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA. The pharmaceutical product will be delivered to the contractor's location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $3,777.10 delivery order for XCOPRI 200 mg tablets (30-count) with a firm fixed price structure and an ultimate completion date of October 27, 2025. This is a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order valued at $1,874.46 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count supply) under a firm fixed-price contract. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,303.70 by the Defense Logistics Agency (DLA) on May 20, 2025, for the supply of XCOPRI 50 mg tablets (30-count). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of May 21, 2025. The contract is being performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger...
- SPE2DR25D1202Indefinite Delivery Contract
- SPE2DR25D1202-SPE2DR26F71UGDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,001.25 to AmerisourceBergen Drug Corp for the supply of XCOPRI 50 MG tablets (30-count units) on October 30, 2025. This firm fixed-price delivery order, with an ultimate completion date of October 31, 2025, was competitively awarded without set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime contract vehicle valued through December 2026 that provides comprehensive global pharmaceutical support to military healthcare programs worldwide. The company's federal contract portfolio demonstrates extensive capability in supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 10/30/25 |